Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Reprocell Inc. (4978:JPX), powered by AI.
Reprocell Inc. is currently trading at ¥128. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Reprocell Inc. on Alpha Lenz.
Reprocell Inc.'s P/E ratio is 115.3.
“Reprocell Inc. trades at a P/E of 115.3 (premium valuation) with modest ROE of 1.2%. 3Y revenue CAGR of 10.1% highlights clear growth momentum.”
Ask for details →Reprocell Inc. is a pioneering company in the life sciences sector, specializing in biotechnology and regenerative medicine. It primarily focuses on the research and development of stem cell technologies. The company offers a wide array of services and products that support drug discovery and development processes, specifically targeting areas such as gene and cell therapy research. Reprocell's portfolio includes induced pluripotent stem cells (iPSCs) and human tissue products that are instrumental in personalized medicine applications. These products assist in enhancing the predictability of drug efficacy and safety in preclinical stages. Reprocell Inc.'s impact extends across pharmaceutical and medical research industries, enabling advancements in disease modeling and therapeutic developments. By providing innovative tools for researchers worldwide, Reprocell plays a significant role in advancing therapies that aim to address various unmet medical needs, underpinning its importance in the biotechnology and healthcare fields.
“Reprocell Inc. trades at a P/E of 115.3 (premium valuation) with modest ROE of 1.2%. 3Y revenue CAGR of 10.1% highlights clear growth momentum.”
Ask for details →Reprocell Inc. (ticker: 4978) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 99 employees. Market cap is $11.9B.
The current price is 128 with a P/E ratio of 115.32x and P/B of 1.33x.
ROE is 1.19% and operating margin is -4.38%. Annual revenue is $3.0B.